Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

China approves Cytokinetics' Myqorzo (aficamten) cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy treatment
Small molecule, cardiovascular, cardiac myosin inhibitor, hypertrophic cardiomyopathy - Read more

Johnson & Johnson's Rybrevant Faspro (amivantamab) receives FDA approval as first subcutaneous EGFR-targeted non-small cell lung cancer therapy
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, EGFR mutation, subcutaneous administration - Read more

Norgine, Vir Biotechnology license hepatitis D combo for Europe, €55M ($64.6M) upfront, €550M ($646M) total
Licensing deal, infectious disease, antibody, milestone payments - Read more

BMS, Harbour BioMed collaborate on multi-specific antibodies, $90M upfront, $1.035B milestones
Research collaboration, antibody, milestone payments, drug discovery - Read more

Boehringer Ingelheim, Galux partner on AI-driven precision protein design research using GaluxDesign platform
Research collaboration, AI/ML, protein design, antibody - Read more

Valink Therapeutics, Nona Biosciences form strategic alliance to accelerate bispecific antibody and ADC discovery
Strategic alliance, oncology, bispecific antibodies, drug discovery, antibody-drug conjugates - Read more

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

ImmunityBio's Anktiva shows 38% three-year disease-free survival in non-muscle-invasive bladder cancer subtype
Protein therapy, cancer, IL-15 receptor agonist, bladder cancer, combination therapy - Read more

Merck & Co.'s Keytruda (pembrolizumab) plus Padcev hits Ph3 endpoints in perioperative muscle-invasive bladder cancer treatment
Antibody, cancer, monoclonal antibody, bladder cancer, PD-1 checkpoint inhibitor, antibody-drug conjugate - Read more

Personalis' NeXT Personal ctDNA test shows early immunotherapy response prediction across advanced solid tumors
Immunotherapy, cancer, immune checkpoint inhibitors, ctDNA biomarker, solid tumors - Read more

Johnson & Johnson's TECVAYLI (teclistamab) plus DARZALEX shows 83% risk reduction in Ph3 relapsed/refractory multiple myeloma trial
Antibody, cancer, bispecific antibody, multiple myeloma, BCMA target, combination therapy - Read more

Addition Therapeutics emerges from stealth with $100M to develop novel gene therapies for chronic, rare diseases
Gene therapy, rare disease, major transaction, strategic - Read more

Cascade Pharmaceuticals raises $46M Series B, phase III trials and pipeline development
Metabolic diseases, small molecule, nuclear receptors, clinical-stage - Read more

T-Curx raises $20M Series A for non-viral CAR-T cancer therapies
CAR-T cell therapy, oncology, non-viral gene transfer, clinical-stage - Read more

Kodiak Sciences raises $160M public offering, precommercial retina focused biotechnology company
Retina therapeutics, precommercial, biotechnology - Read more

Alnylam Pharmaceuticals invests $250M to expand RNAi manufacturing facility using new enzymatic ligation technology
RNAi therapeutics, cardiovascular, operational, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Vistagen's fasedienol (PH94B) fails Ph3 trial for social anxiety disorder despite previous positive results
Small molecule, anxiety disorders, intranasal therapy, social anxiety disorder, chemosensory modulation - Read more

Intercept Pharmaceuticals restructures with 146 layoffs following Ocaliva withdrawal from U.S. market
Small molecule, rare disease, operational, cost reduction - Read more

Voyager Therapeutics lays off 30 employees after Novartis returns rights to two discovery programs
Gene therapy, neurological, operational, cost reduction - Read more

Biosecure Act heads to Trump's desk, targeting Chinese biotech companies in defense bill
Biotech services, regulatory, strategic, operational - Read more

Fired NIAID director Marrazzo sues Trump officials seeking reinstatement claiming illegal whistleblower retaliation
Infectious disease, regulatory, operational, strategic - Read more

CDC ends routine newborn hepatitis B vaccination, recommends delaying dose until two months
Vaccine, infectious disease, operational, strategic - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here